Hence, our experiments suggest that TRAIL and TRAIL-R2 may be negative regulators in AT2R-mediated apoptosis in DU145 cells, and the combined treatment with AT2R overexpression and TRAIL-R2 downregulation might be promising as a new gene therapy against human prostate cancer. This evidence concerns the gene TNFRSF10B and prostate carcinoma.